Current Therapy of Rheumatoid Arthritis (Recent Therapeutics Policies of Rheumatoid Arthritis part 2)

Hendrata Erry Andisari


Therapy in RA has undergone many advances today and in line with knowledge of the pathogenesis of RA, the current therapeutic goal is to alter the journey and control the activity of RA disease. Several groups of drugs have been used in RA therapy including non-steroidal anti-inflammatory drugs (NSAIDs), conventional disease-modifying antirheumatic drugs (DMARDs) as well as biological agents (bDMARD), glucocorticoids and anti-pain medicines. In recent years, the development of biological agents that have specific targets for inflammatory mediators such as interleukin (IL) -1, IL-6 and Tumor Necrosis Factor (TNF) suggests a potent therapeutic effect on RA. In this article will be presented the latest biological agents as the latest therapy on RA.


Keywords : conventional DMARDs, biological agents

Full Text:



Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modyfing antirheumatic drugs: 2013 update. Ann Rheum Dis. 2013; 13: 1-18.

Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol. 2012;39:1559–82.

Iskandar A, Wachjudi RG. Diagnosis dan Penatalaksanaan Artritis Reumatoid, Himpunan Makalah Lengkap Rheumatologi Klinik Bandung. Bandung: Pusat Informasi Ilmiah Departemen Ilmu Penyakit Dalam FK Universitas Padjajaran, 2014: 309-340.

Aletaha D, Martinez-Avila J, Kvien TK, Smolen JS. Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. Ann Rheum Dis 2012;71:1190–6.

Heimans L, Wevers-de Boer KV, Visser K, Goekoop RJ, Oosterhout MV, Harbers JB, et al. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis. 2013;374:459–66.

Graudal N, Jurgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum. 2010;62:2852–63.

Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, et al. Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis: A Randomized Trial. Ann Intern Med. 2012;156:329–39.

Kiely P, Walsh D, Williams R, Young A. Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity—the early RA network (ERAN). J Rheumatology. 2011;50:926–31.

Cash J.M, Klippel J.H,. Second-Line Drug Therapy for Rheumatoid Arthtritis. New England J Medicine 1994;330 (19):1368–1376.

Strangfeld A, Hierse F, Kekow J, Hinueber UV, Tony HP, Dockhorn R, et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis. 2009;68:1856–62.

Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309:887–95.

Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: Twentysix cases reported to the food and drug administration. Arthritis Rheum. 2002;46(12):3151–3158.

Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, Kaipiainen-Seppanen O, et al. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). Ann Rheum Dis. 2013;72:851–7.

van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of randomised trial. Lancet. 2009;374:459–66.

Smolen JS, Han C, Van der Heijde DM, Emery P, Bathon JM, Keystone E, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNF-blockade. Ann Rheum Dis. 2008;68:823–7.

Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675–81.

Moreland LW, O’Dell JR, Paulus HE, Curtis JR, Bathon JM, Clair EW, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum. 2012;64:2824–2840.

Emery P, Hammoudeh M, Fitzgerald O, et al. Assessing maintenance of remission with reduced dose etanercept plus methotrexate, methotrexate alone, or placebo in patients with early rheumatoid arthritis who achieved remission with etanercept and methotrextate: the PRIZE study. Ann Rheum Dis 2013;72(Suppl 3):399-415.

Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64–71.

Burmester G, Kivitz A, Kupper H, Arulmani U, Florentinus S, Goss SL, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: results from the CONCERTO trial. Ann Rheum Dis. 2013;72(Suppl 3):72-92.

Fleischmann R, van Vollenhoven RF, Smolen JS, et al. Long-Term Outcomes of Early Rheumatoid Arthritis Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach. Arthritis Rheum. 2012;64(Suppl):S335–6.

Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60(8): 2272–2283

Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374:210–221.

Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:909–20.

Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010;62:2625–32.

Schiff M, Fleischmann R, Weinblatt M, Valente R, Heijde D, Citera G, et al. Head to head comparison of subcutaneus abatacept versus adalimumab for rheumatoid arthritis: Findings of phase IIIb, multinational, prospective, randomised study. Ann Rheum Dis. 2013;71(3):28-38.

Westhovens R, Kremer JM, Moreland LW, Emery P, Russell AS, Li T, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol. 2009;36(4):736–742.

Gabay C, Emery P, van VR, Vollenhoven R, Dikranian A, Alten R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381:1541–50.

Morel J, Duzanski MO, Cantagrel A, Combe B, Dougados M, Flipo RM, et al. Prospective follow-up of tocilizumab treatment in 1100 patients with refractory rheumatoid arthritis: tolerance data from the french registry regate (registry–roactemra). Ann Rheum Dis 2013;72 (3):456-470.

Burmester GR, Rigby W, van Vollenhoven R, Kay RF, Rubbert-Roth J, Kelman A, et al. Tocilizumab (TCZ) in combination and monotherapy versus methotrexate (MTX) in MTX-naive patients (pts) with early rheumatoid arthritis (RA): clinical and radiographic outcomes from a randomised, placebo-controlled trial. Ann Rheum Dis. 2013;72(l):41-63.

Alten RE, Zerbini C, Jeka S, Irazoque F, Khatib F, Emery P, et al. Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. Ann Rheum Dis. 2010;69(2):364–367.

Genovese MC, Kavanaugh A, Peterfy CG, Magilavy D. An oral syk kinase inhibitor in the treatment of rheumatoid arthritis (RA): a 3 month randomized placebo controlled phase 2 study in patients with active RA who had failed biologic agents. ACR. 2009; 70:909–20.

Lee EB, Fleischmann RM, Hall S, et al. Radiographic, Clinical and Functional Comparison of Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Nave Patients with Rheumatoid Arthritis. Arthritis Rheum 2012;64(Suppl): S1049. Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309:887–95.

Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A singleblind randomised controlled trial. Lancet. 2004;364(9430):263–269.

Kiely P, Walsh D, Williams R, Young A. Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity—the early RA network (ERAN). J Rheumatology. 2011;50:926–31.



  • There are currently no refbacks.

Copyright (c) 2018 Oceana Biomedicina Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.



Duplication checking by:

Plagiarism detection by:


Published by: Universitas Hang Tuah, Surabaya, Jawa Timur, Indonesia

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.